Skip to main content

Table 1 Characteristics of studies included in the AR-V7-positive proportion meta-analysis

From: The characteristics of androgen receptor splice variant 7 in the treatment of hormonal sensitive prostate cancer: a systematic review and meta-analysis

Author Year Country   Newly diagnosed PCa CRPC
    AR-V7 detection assay Patients (n) Age (range) Gleason score (range) Median PSA (ng/ml) at sampling (range) Patients (n) Age (range) Gleason score (range) Median PSA (ng/ml) at sampling (range) Follow-up time (month) Median (range)
Horenberg [19] 2011 Sweden Tissue RNA 10 79 (60–85) - 156 (21–10,000) 30 73 (54–88) - 335 (4–5139) -
Hu [6] 2009 USA Tissue RNA 82 - - - 25 - 7 (5–9) - -
Qu [15] 2015 China IHC 104 70 (43–84) 8 122.5 (3.0–6006.2) 46 65 (50–79) 8 98 (2.6–2350.0) 25 (2–132)
Welti [24] 2016 UK IHC 33 - - - 35 67.5 (IQR64.2–75.3) - - -
Zhang [32] 2011 USA IHC 50 - - - 162 63 (42–93) - 12.4 (1.7–4000) -
Zhu [ 21] 2018 USA RISH 9 - - - 28 64 (52-86) - 59.6 (0.7-6746.8)  
UK RISH 0 - - - 16 72.3 (48.8-79.4) - 177.0 (2.6-4098.0)  
Takeuchi [ 28] 2016 Japan Whole blood RNA 20   - - 23 - - - -
Lee [30] 2017 Korea Tissue RNA 13 - 7 (6-9) 12.76 (2.75-40.92) 3 65.3 (56-70) 8 (8-10) 8.78 (8.6-173.7) -
Saylor [22] 2017 USA RISH 30 - 7 (6–10)   12 - - - -
Kallio [23] 2018 Finland IHC/RNA-seq 24 - 7 6.3 (4.1-21.0) 30 - - - -
Nimir [26] 2019 Australia CTC RNA/ctRNA/Exosome RNA 12 - - - 32 - - - -
Sharp [40] 2019 USA IHC-
ICR/RMH 63 61.7 (SD=7.52) >7 (67%) 51.7 (IQR 20.3-145.0) 160 68.5 (IQR 63.9-73.1) - 230.5 (IQR 77.0-591.5) -
UW 128 60 (SD=8.21) >7 (70%) 6.3 (IQR 3.3-67.0) - - - -
Woo [29] 2018 Korea Urinary Exosome RNA 22 70 (51-84) >7 (14%) 1.01 (0.005-1667) 14 71.5 (60-82) >7 (71.5%) 19.38 (0.006-646) -
Park [31] 2019 Korea Tissue RNA 19 65.9 (52-79) >7 (58%) - 19 - >7(84%) - 46(1-158)
Nakazawa [27] 2015 USA CTC mRNA 2 53.5
(50–57)
9 339.5 (314–365) 12 67 (56-82) >8 (91.7%) 159.5 (2.2-895) 11 (6–18)
  1. PCa prostate cancer, CRPC castration resistance prostate cancer, PSA prostate specific antigen, AR-V7 androgen receptor splicing variant 7, CI confidence interval